人造血淋巴系统小鼠在急性白血病模型构建中的应用进展

摘要/Abstract

摘要：

为了研究人类造血功能异常，学者们不断改进和发展白血病干细胞的异种移植模型。构建理想的异种移植模型，真实地模拟疾病，在研究人类白血病的分子机制及完善其治疗方案中尤为重要。人造血淋巴系统小鼠(humanized hematolymphoid system mice，HHLS)是异种移植了人源血细胞或组织的免疫缺陷鼠或者表达人类基因的人鼠嵌合体(mouse human chimaeras)或称人源化小鼠(humanized mice)。理想的人源化小鼠即是人类移植物在空间和功能上完全替代小鼠的内源性造血和免疫系统。要实现这一目标，需要满足三个基本要求:首先，受体小鼠需要具有先天或者后天的免疫缺陷，以防止小鼠内源性免疫系统对人体移植物的异种移植排斥；第二，小鼠体内需要产生适合人类细胞生存的微环境;第三，人类细胞需要从小鼠体内获得支持性交叉反应信号。本文对HHLS模型的最新研究进展作一综述。

关键词: 人造血淋巴系统小鼠, 异种移植, 急性白血病

Abstract:

Despite a continuous improvement in xenograft models, engraftment of human malignant cells remains challenging in research of human hematopoiesis.In order to investigate the molecular mechanism involved in human leukemia and to improve therapy, establishing xenograft models that faithfully replicated the disease is critically important. Humanized mice are generated by transplanting human hematopoietic cells into recipient mice. An ideal model would be a humanized mouse in which the human graft fully replaces the endogenous mouse hematopoietic and immune systems. For this purpose, there are three basic requirements: tolerance by the mouse host, correct spatial location and appropriately cross-reactive support and interaction factors such as cytokines and major histocompatibility complex molecules.Here we review the achievements, most recent developments, and the remaining challenges in the generation of pre-clinically-predictive systems for human hematology, which closely resembling the human situation in the xenogeneic mouse environment.

Key words: humanized hemato-lymphoid system mice, xenograft, acute leukemia

中图分类号:

R733.7

程丽艳，屠凌岚，颜冬梅，王孝举，郑晓亮. 人造血淋巴系统小鼠在急性白血病模型构建中的应用进展[J]. 中国临床药理学与治疗学, 2017, 22(10): 1195-1200.

CHENG Liyan，TU Linglan，YAN Dongmei，WANG Xiaoju，ZHENG Xiaoliang. Progress in application of humanized hemato-lymphoid system mice in human acute leukemia model[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1195-1200.

参考文献

［1］Hoshii T,Tadokoro Y,Naka K,et al.mTORC1 is essential for leukemia propagation but not stem cell self-renewal［J］.J Clin Invest,2012,122(6):2114-2129.
［2］Bobbala D, Kandhi R,Chen X, et al.Interleukin-15 deficiency promotes the development of T-cell acute lymphoblastic leukemia in non-obese diabetes mice with severe combined immune- deficiency［J］. Leukemia, 2016,30(8)：1749-1752.
［3］Fortier JM, Graubert TA.Murine models of human acute myeloid leukemia［J］. Cancer Treat Res, 2010, 145(145):183-196.
［4］Marschalek R.Mechanisms of leukemogenesis by MLL fusion proteins［J］.Br J Haematol，2011,152(2):141-154.
［5］Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells［J］.Int J Hematol,2005,82(5):389-396.
［6］Bonnet D.Normal and leukaemic stem cells ［J］.Br J Haematol,2005,130(4):469-479.
［7］Hope KJ, Jin L, Dick JE.Acute myeloid leukemia originates from a hierarchy of leukemic stem cell slasses that difer in self-renewal capacity ［J］.Nat Immunol,2004,5(7):738-743.
［8］Fortier JM, Graubert TA. Murine models of human acute myeloid leukemia［J］. Cancer Treat Res，2010,145:183-196.
［9］McCormack E, Bruserud O, Gjertsen BT.Animal models of acute myelogenous leukaemia-development, application and future perspectives［J］. Leukemia, 2005,19(5):687-706.
［10］Shultz LD,Ishikawa F,Greiner DL.Humanized mice in translational biomedical research［J］.Nat Rev Immunol,2007,7(2):118-130.
［11］Shuhz LD,Brehm MA,Garcia-Martinez JV,et al.Humanized mice for immune system investigation:progress,promise and challenges［J］.Nat Rev Immunol,2012,12(11):786-798.
［12］Agliano A,Martin-Padura I,Mancuso P,et al.Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains［J］.Int J Cancer,2008,123(9):2222-2227.
［13］Brehm MA, Racki WJ, Leif J, et al.Engraftment of human HSCs in nonirradiated newborn NOD-scid IL2rgamma null mice is enhanced by transgenic expression of membrane-bound human SCF［J］.Blood,2012,119(12):2778-2788.
［14］Ito R, Takahashi T, Katano I, et al.Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice［J］. J Immunol,2013,191(6):2890-2899.
［15］Meyer LH, Debatin KM.Diversity of human leukemia xenograft mouse models: implications for disease biology［J］. Cancer Res，2011,71(23):7141-7144.
［16］Reinisch A, Thomas D, Corces MR, et al.A humanized bone marrow ossicle xenotransplant- ation model enables improved engraftment of healthy and leukemic human hematopoietic cells［J］.Nature Med, 2016, 22(7):812-821.
［17］Kong Y, Yoshida S, Saito Y, et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL［J］. Leukemia, 2008, 22(6):1207-1213.
［18］Spiegel A, Kollet O, Peled A, et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling［J］.Blood,2004, 103(8):2900-2907.
［19］Willinger T, Rongvaux A, Strowig T, et al. Improving human hemato- lymphoid -system mice by cytokine knock-in gene replacement［J］. Trends Immunol, 2011, 32 (7):321-327.
［20］Aliperta R,Cartellieri M,Feldmann A,et al.Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts［J］.Blood Cancer J,2015,5(9):e348.
［21］Wunderlich M,Chou FS, Link KA, et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3［J］. Leukemia, 2010, 24(10):1785-1788.
［22］Cosgun KN, Rahmig S, Mende N, et al.Kit regulates HSC engraftment across the human-mouse species barrier［J］. Cell Stem Cell,2014,15(2):227-238.
［23］McIntosh BE, Brown ME, Duffin BM, et al. Nonirradiated NOD,B6.SCID Il2rgamma-/- Kit(W41/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells［J］. Stem Cell Reports,2015,4(2):171-180.
［24］Rongvaux A, Willinger T, Takizawa H, et al.Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo［J］. Proc Natl Acad Sci USA,2011, 108(6):2378-2383.
［25］Mendelson A, Frenette PS.Hematopoietic stem cell niche maintenance during homeostasis and regeneration［J］. Nature Medicine, 2014, 20(8):833-846.
［26］Chalign R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: Only the MPL W515 mutations promote a G1/S-phase transition［J］. Leukemia,2008,22(8):1557-1566.
［27］Friedenstein AJ, Gorskaja JF, Kulagina NN.Fibroblast precursors in normal and irradiated mouse hematopoietic organs［J］. Exp Hematol，1976,4(5):267-274.
［28］Luria EA, Owen ME, Friedenstein AJ, et al. Bone formation in organ cultures of bone marrow［J］. Cell Tissue Res，1987，248(2):449-454.
［29］Chen Y, Jacamo R, Shi YX, et al.Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment［J］. Blood，2012, 119 (21) :4971-4980.
［30］Groen RW, Noort WA, Raymakers RA, et al.Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma［J］.Blood，2012,120(3):e9-e16.
［31］ Doulatov S, Notta F, Laurenti E, et al. Hematopoiesis: A Human Perspective［J］. Cell Stem Cell, 2012, 10(2):120-136.
［32］Manz MG. Human-hemato-lymphoid-system mice: opportunities and challenges ［J］. Immunity, 2007, 26(5):537-541.
［33］Rongvaux A, Takizawa H, Strowig T, et al. Human Hemato-Lymphoid System Mice: Current Use and Future Potential for Medicine［J］. Immunol, 2013, 31(31):635-674.
［34］Li L,Bhatia R.Stem cell quiescence［J］.Clin Cancer Res,2011,17 (15):4936-4941.
［35］Brehm MA, Cuthbert A, Yang C, et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation.［J］. Clin Immunol, 2010, 135(1):84-98.
［36］Covassin L, Jangalwe S, Jouvet N, et al. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells［J］. Clin Exp Immunol, 2013, 174(3):372-388.
［37］McCune JM, Namikawa R, Kaneshima H, et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function［J］.Science,1988,241(4873): 1632-1639.
［38］Greenblatt MB, Vrbanac V, Tivey T, et al. Graft versus host disease in the bone marrow, liver and thymus humanized mouse model ［J］. Plos One, 2013, 8(5):e44664.
［39］Lapidot T, Pflumio F, Doedens M, et al.Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice ［J］. Science,1992,255(5048):1137-1141.
［40］Deng K, Pertea M, Rongvaux A, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations［J］.Nature,2015,517(7534):381-385.
［41］Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche ［J］. Cell Stem Cell, 2007, 1(6):685-697.
［42］Satoh Y, Matsumura I, Tanaka H, et al.C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells［J］. Leukemia, 2011, 26(2):303-311.
［43］Schr?der JK, Kolkenbrock S, Tins J, et al. Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia［J］. Leuk Res, 2000, 24(5):401-409.
［44］Rongvaux A, Willinger T, Martinek J, et al.Development and function of human innate immune cells in a humanized mouse model［J］.Nat Biotechnol,2014,32(4):364-372.
［45］Lee MW, Kim HJ, Yoo KH, et al. Establishment of a bioluminescent imaging-based in vivo leukemia model, by intra-bone marrow injection［J］.Int J Oncol, 2012, 41(6):2047-2056.
［46］Nwajei F, Konopleva M.The Bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells［J］. Adv Hematol, 2013, 2013(8): 953982.
［47］Kremer KN,Dudakovic A,Mcgeelawrence ME,et al.Osteoblasts protect AML cells from SDF-1-induced apoptosis［J］.J Cell Biochem,2014,115(6):1128-1137.
［48］Asiedu KO, Koyasu S, Szajek LP, et al. Bone marrow cell trafficking analyzed by 89Zr-oxine positron emission tomography in a murine transplantation model［J］. Clin Cancer Res，2017，23(11):2759-2768.

[1]	郑燕华, 陈峪, 顾磊. 美罗培南与头孢哌酮钠/舒巴坦钠治疗急性白血病合并重症肺部感染的疗效观察[J]. 中国临床药理学与治疗学, 2014, 19(3): 309-312.
[2]	郭维, 冉福香, 王瑞卿, 崔景荣, 李润涛, 程铁明, 葛泽梅. 4-甲基哌嗪-1-二硫代甲酸-(3-氰基-3, 3-二苯基)丙酯盐酸盐在小鼠的抗肿瘤作用[J]. 中国临床药理学与治疗学, 2004, 9(1): 59-62.